DD
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PR should be out soon...
The big bounce is coming soon...
Pre-planned fda meeting to get IND approval soon!
Animal studies will be successful in my opinion
PR coming soon!
Let's go PPCH. People, believe! Slap the ask. Propanc will be successful whether you buy in now or not; but now is the perfect time to make the big $$$ in the coming months. PR's are coming!
but if PRP gets ODD status, its on a fastback to human trials. financiers will be knocking down Propanc doors to put up the $$ for the studies. with ODD status, could be 3-5 months for human trials underway. fingers crossed for that!
No doubt once IND status granted, human trials underway, eventual FDA approval, a couple of products on the market--PPCH is out of OTC altogether. But I think they are interested in licensing PRP to big pharma. I predict that completed by 1/2016
Ready for a run? DMHI is gonna take off with or without you. Slap the ask and let's move the pps to .05-.1. Hoping for this by end of week....
Contagion: Group Panic Accounts for Current Drop in PPS.
PPCH investors are an anonymous group of shareholders. According to social psychologists, what first occurred is known as submergence, whereby many (but not all) investors have lost their sense of individual self and personal responsibility as shareholders (i.e. making rational decisions about whether to buy or sell based on objective facts). This is quite heavily induced by the anonymity of the crowd and happens with every group of shareholders in any company.
What is occurring now with PPCH is known as contagion or the propensity for investors of PPCH to unquestioningly follow the predominant ideas and emotions of the crowd. For those of you "submerged" in the PPCH investor groups' fearful and doubtful emotions and ideas (i.e. you've lost reason) PANIC has spread much like a disease.
Hence, the current PPS. This is a company with amazing potential that is perhaps, the most undervalued on the OTC market.
Reverse Split: Not Gonna Happen (SEE EXCERPT FROM LATEST PR)
"Just prior to filing the Company's last quarterly report, the Company terminated all financing arrangements with Southridge Capital and continues to build relationships with institutional investors keen to become involved with the Company as it seeks to establish and build its cancer treatment portfolio. "Whilst it is regrettable we needed to alter our financing arrangements, I am delighted to receive interest from new investors who can assist the company. In addition, we have also seen our number of shareholders quadruple over the last quarter, so right now, my priority is to increase shareholder value by advancing our lead products to commercialization," Mr. Nathanielsz commented."
Nothing to me indicated that CEO Nathanielsz is even considering a R/S, even reading between the lines...
IMO, Propanc is the opposite of other OTC market scam companies. Just take a look at the credentials, expertise, and experience of their Board of Directors and Scientific Board. This company has value in the long term and they know how to take a drug to market; for goodness sake, John Smythe (on the Scientific Board) is Chairs of the Expert Advisory Group for Oncology & Haematology for the Commission on Human Medicines and serves on the Expert Oncology Advisory Group to the European Drug Licensing Board. If he has confidence that PRP will get FDA approved, I have no reason to believe he would ever be wrong. Remember, FDA approval require safety and efficacy and so far, all Propanc's pilot studies (ion animals and humans) have proven both. Also, I do not foresee them delivering us a R/S. They value their shareholders commitment to the company and once they get FDA approval for PRP as IND, they will have financiers waiting in line to put up the cash. They don't need to R/S and ruin their relationship with shareholders. And if they were gonna do a r/s there have been many opportunities for them to do so, much more ideal than the current PPS. I am going to email them and let them know investors concerns about R/S and see if I get a response. If this was one of the thousands of other companies on the OTC, I would tend to agree with you. But here, I just can't. I see Propanc moving to Nasdaq by years end, with a PPS in the $1-3 range and a revolutionary cancer drug line that can be used a primary treatment or in adjunct with chemotherapy.
Propanc has huge potential, no revenue in R&D is so common. Are you familiar with the process by which an R&D company goes public and the process by which a drug reaches the market place? If you knew about either of these, or anything about Propanc, you woudn't be making such statements--simply uninformed. FDA apporval, IND status and PRP on the market is a reality by year's end, IMO.
You too KngmAz. Just confused here....
SOOOO Undervalued! Why are you selling??? and why not buying???
Can't wait for FDA approval....
Southridge is now officially out of the picture; see last PR.
Would love to see DHMI hit .01 tomorrow!!!!!!!!!!!!!!!
Rapid Improvement Inc.: DMHI Partner. One very innovative partnership is with Rapid Improvement, Inc., a Natural Language Processing (NLP) technology company in Washington, D.C. This is unique to the Virtual Physicians Network mobile platform and sought after by numerous EMR companies. Possible buyout of DMHI IMO, or new partnerships are around the corner.
Here is the link for Rapid Improvement Inc. These guys are as legit as DMHI: tellmymd.com
insert-text-here
DMHI still flying under the radar. Some more attention from investors and this will take off and run....IMO
Agreed; its been downhill and also agree rebound is coming.
Just will take time for investors to rebuild confidence. At least now we have tangible future plans ahead for PPCH--BIG PLANS!
FDA IND approval would put PPCH pps well beyond .015, IMO. This is a serious R & D company with a potentially revolutionary cancer treatment. As far from a "dumparoo" as you can get....IMO
Company has huge potential: Animal efficacy studies underway, FDA pre-IND meeting in the works, Human Trials around the corner, Cancer marketplace is huge $$$$. This stock is going to be well above .05 by end of the year. We'll be in dollar land, IMO.
PROPANC New Institutional Investors:
According to CEO Nathanielsz, Propanc "continues to build relationships with institutional investors keen to become involved with the Company as it seeks to establish and build its cancer treatment portfolio."
Propanc's #1 Priority: Increase Shareholder Value!
According to CEO nathanielsz, "my priority is to increase shareholder value by advancing our lead products to commercialization...."
New Investors! Propanc's CEO says "I am delighted to receive interest from new investors who can assist the company."
BIG NEWS! CEO Says Pronpanc is "is significantly undervalued"
The planned animal studies are designed to better understand PRP's mode of action, how the drug is distributed and breaks down in the body, its effectiveness in inhibiting metastases and associated biological markers, as well as prolonging survival in animals, key information from a regulatory and marketing perspective.
As part of the overall implementation of R&D activities and marketing efforts to licensees, Propanc has engaged in strategic relationships with a Quality Supplier for the ordering of the active pharmaceutical ingredients for the PRP formulation, a specialized Contract Research Organization offering preclinical services for testing cancer agents, as well as an International Business Development Consultancy Firm to actively market PRP globally to potential buyers, once the animal studies are completed. "I am pleased to have commenced the next development stage for PRP, which is pivotal for our progression to human trials. Strategic relationships formed with experts in the industry gives us confidence we have the support infrastructure needed to successfully complete these studies, and beyond," said James Nathanielsz, Propanc's Chief Executive Officer. "Furthermore, raising funds from investors to commence these studies demonstrates their excitement and interest in further developing PRP. As a potential new class of targeted therapeutic agents effective against metastatic cancer, we believe our Company is significantly undervalued compared to similarly placed competitors who enjoy a much higher valuation," he added.
Just prior to filing the Company's last quarterly report, the Company terminated all financing arrangements with Southridge Capital and continues to build relationships with institutional investors keen to become involved with the Company as it seeks to establish and build its cancer treatment portfolio. "Whilst it is regrettable we needed to alter our financing arrangements, I am delighted to receive interest from new investors who can assist the company. In addition, we have also seen our number of shareholders quadruple over the last quarter, so right now, my priority is to increase shareholder value by advancing our lead products to commercialization," Mr. Nathanielsz commented.
Propanc's Pilot Animal Studies: Success!
Propanc has already completed pilot animal studies with great success:
PRP
Proven Anti- Tumor Activity in Mice
?? Anti-tumoractivityassessedinB- 16-F10 melanoma model.
? Treatment began 7 days post implant.
? Relative tumor volumes significantly smaller compared to control.
? PRPhasanti-tumoractivity,but without severe, or even serious side effects associated with chemotherapy.
PPCH Scientific Expertise: FDA Approval: No Problemo!!
Their scientific advisory board has been there, done that and have the t shirt:
Professor John Smyth
John Smyth has for the past 25 years served as Chair of Medical Oncology in the University of Edinburgh Medical School, where his major research interest is the development and evaluation of new anti-cancer drugs. He has published over 300 papers and is Editor-in-Chief of the European Journal of Cancer. He served for several years on the UK Committee on Safety of Medicines; currently Chair's the Expert Advisory Group for Oncology & Haematology for the Commission on Human Medicines and serves on the Expert Oncology Advisory Group to the European Drug Licensing Board.
He is a fellow of the Royal College of Physicians of Edinburgh and London, and fellow of the Royal Society of Edinburgh. He is a past-president of the European Society of Medical Oncology and was from 2005 – 2007 President of the Federation of European Cancer Societies.
Professor Karrar A Khan
Professor Khan has over 35 years of experience in drug discovery, pharmaceutical development, registration and management of pharmaceutical scientists. Professor Khan has also held various product development and management positions with Abbott Laboratories and Beecham Pharmaceuticals. In these roles, he developed medicines for several therapeutic areas including antibiotics, anti depressant, anti inflammatory, anti obesity, psychosis, cardiovascular, pain, cancer, Parkinson’s disease and diabetes.
Professor Khan developed and contributed to the launch of two once a day controlled release dosage forms. His expertise ranged from development for phase 1 to phase 3- 4 and significant experience of bringing prescription and OTC products to market on a worldwide bases (contributed to the registration and launch of over 60 pharmaceutical products). He is a qualified person under the EC quality assurance directive. He now works as a pharmaceutical development consultant.
Professor Khan has authored or co-authored more than 40 scientific publications and is an inventor of several development patents. He has been an invited speaker at many national and international conferences.
Dr. Ralf Brandt
Dr. Brandt is the co-founder of vivoPharm. He is a biochemist and cell biologist with over 15 years experience in research programs of experimental oncology. Furthermore, he has immense experience in in vivo pharmacology and anti-cancer drug profiling. He received his Licence (BSc in Biochemistry and Animal Physiology) in 1986, and his PhD (in Biochemistry) in 1991 from the Martin-Luther University of Halle-Wittenberg, Germany. Dr. Brandt was employed at research positions at the National Cancer Institute in Bethesda, MD, USA and at Schering AG, Germany.
Since 1990, Dr. Brandt has been active in the field of preclinical oncology. He led the tumor Biology program at Novartis Pharma AG, Switzerland and established several transgenic mouse lines developing tumors under the control of oncogenes.
During Dr. Brandt's long career in the pharmaceutical industry he has acquired significant knowledge and expertise in leading business units and representation of services to the pre-clinical research market. Dr. Brandt is a member of the Scientific Advisory Board at Receptor Inc. in Toronto Canada.
Propanc's Experetise!
Mr James Nathanielsz Chief Executive Officer
Director & C.E.O, Oct ‘07.
15 yrs. experience in R&D, Manufacturing & Distribution, including 10 yrs. in oncology
Bachelor of Applied Science (Biochemistry/Applied Chemistry) & Master of Entrepreneurship & Innovation, Swinburne University, Melbourne, Australia.
Dr Julian Kenyon Chief Scientific Officer
Co-Founder & Director, Feb ‘08.
Medical Director of the Dove Clinic for Integrated Medicine, UK, since 2000.
Bachelor of Medicine & Surgery & Doctor of Medicine , University of Liverpool.
Primary Fellow of the Royal College of Surgeons, Edinburgh for over 40 years.
Prof. Klaus Kutz Chief Medical Officer
15 yrs. experience as consultant in Clinical Pharmacology & Safety in oncology.
12 yrs. experience Head of Clinical Pharmacology in 2 multinational pharma companies.
Specialist for Internal Medicine, Gastroenterology & Clinical Pharmacology.
Professor of Medicine, University of Bonn, Germany.
Propanc is trading on a concrete and tangible product, a scientific board of directors whose expertise and track record is more than commendable and a board of directors who hold stock holders interests in high regard.
With animal studies complete--safe and efficacious-- Propanc will have the leverage to negotiate financing human trials. With the cancer marketplace encompassing massive $$$, that would be enough for any financier to put up the $$ to finance human trials and Propanc would have the negotiating power to achieve the terms of agreement they want.
The abstract potential of Propanc is becoming more and more concrete. PPS will gradually increase, and the authorized shares as well; the two are not mutually exclusive with time.
Here we go.
Planned pre-IND meeting with the FDA.
Sounds like it's already in the works. The animal studies completed thus far already show safety and efficacy of PRP! We are in good shape (see Propancs 01/15 investor presentation).
Potential financiers will be knocking down Propanc's door with offers once IND status is approved, and then Propanc will have the leverage to get the terms of agreement they are seeking.
Human Trials Will Happen, IMO. As a researcher myself, I have worked on numerous clinical trials and if there is enough evidence for animal studies to take place (and Propanc has already obtained positive result from pilot studies of both humans and animals) it undoubtedly means human trials are around the corner.
Take the time to investigate the scientific board of Propanc. These fellows are top tier researchers, with experience taking numerous drugs through FDA approval and into the marketplace with great success.
Propanc's scientific board and board of directors also know their drug PRP is revolutionary and I am not surprised they are have trouble reaching a agreement with potential financiers. The terms of agreement have to be right for Propanc because they know they have a drug that will substantially improve the treatment of cancer.
Propanc January 2015 Investor Presentation.
What to Expect! And it's Good!
insert-text-here
Thoughts....
In the big picture (i.e. getting the Propanc Drug line FDA approved and to the market) the increase in authorized stock may be what Propanc needs to raise additional capital to fund their Clinical Trials and it will certainly attract additional investors. I sincerely hope that PPCH investors expand way beyond us few at investorshub. Sure, the pps might drop in the short term, but in terms of PPCH making it to the market place, this may be what they need to do, which in the end, is good if you're patient and hold on.
You've done your DD, Kenny6. Propanc is gonna revolutionize cancer treatment. This company has value, intellectual value, that will eventually turn into big $$$$
It'll turn around. Bounce Time You will be back to even in no time. I Firmly believe these guys can get the money; they have many resources and its sounds like they just have problems with terms of agreement. In the end, though, they'll do what they need to do to get PRP FDA approved and in the marketplace. After all they have sunk into developing the PRP drug line, they're losses would be too great to through in the towel versus agree to an investment in which the terms of agreement are not ideal.
This is very common for R&D companies who are developing new drugs. They revenue comes later, my friend.
Cash is Coming: Southridge still has Propanc listed as one of their companies they are investing in:
insert-text-here
IMO, that is not a dead deal nor has that been confirmed by the Propanc's CEO Mr. Nathanielsz. He simply said that "an alternative course of action may be necessary to raise the capital needed."
Honest Company: I find it very forthcoming that Propanc offered a "no guarantee" of funding in their 10K/10Q. These guys are true professionals and have integrity. I do not see them performing a RS given their dedication to their shareholders. My DD tells me the scientific board and board of advisors are very resourceful. They will be able to procure the funding they need to bring the Propanc drug line to human trials, and eventually the marketplace--they have the connections. For example, take Professor John Smyth:
**Emeritus Professor of Medical Oncology in the University of Edinburgh, where his major research interest has been the development and evaluation of new anti-cancer drugs.
**He has published over 300 papers and is past Editor-in-Chief of the European Journal of Cancer.
**He served for several years on the UK Committee on Safety of Medicines; currently Chair's the Expert Advisory Group for Oncology & Haematology for the Commission on Human Medicines and has served on the Scientific Advisory Group for Oncology to the EMEA.
**He is a fellow of the Royal College of Physicians of Edinburgh and London, and fellow of the Royal Society of Edinburgh.
**He is a past-president of the European Society of Medical Oncology and was from 2005 - 2007 President of the Federation of European Cancer Societies.